Description
Cerebrolysin is a complex mixture of low-molecular-weight peptides and free amino acids obtained from enzymatic cleavage of porcine brain tissue. This makes cerebrolysin fundamentally different from synthetic single peptides like semax or selank: it is a defined peptide mixture, not a single molecule.
In research literature, cerebrolysin has been studied since the 1970s and is among the oldest continuously researched neuropeptide compounds. The research focus lies on neuroprotection and neuronal plasticity. Mechanistically, cerebrolysin acts in preclinical studies like a cocktail of neurotrophic factors, with documented effects on BDNF signaling, neuronal differentiation and inhibition of apoptotic pathways.
The clinical database is particularly extensive in the area of ischemic stroke and cognitive impairment research. The CARS trials (Cerebrolysin and Recovery After Stroke) are the best-known phase 3 studies that have documented effects on neurological recovery endpoints.
A particularity of cerebrolysin: it is not distributed in 10-vial packs of single vials in research practice, but in 6-pack configurations. This standard has historical reasons and is the established research configuration.
Cerebrolysin is available as lyophilized powder in a 6-pack with 60mg per vial (360mg total). Reconstitute with bacteriostatic water before use (3ml per vial = 20mg/ml).
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Cerebrolysin is considered well tolerated per study reports and is among the longest and most extensively clinically studied neuropeptide compounds.
Observed in research and user reports:
- Injection site: mild redness, warmth or pressure at the injection site is the most common local observation.
- Circulation: clinical studies have occasionally described dizziness, mild headache or a sensation of warmth, particularly with overly rapid administration.
- Porcine origin: cerebrolysin is obtained from porcine brain tissue, a defined peptide mixture rather than a single molecule, which limits batch-to-batch consistency and mechanistic clarity compared to mono-peptides.
- Long-term data: the clinical data base is substantial, but it focuses on defined indications and limited treatment periods.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial - Stroke 2016: Randomized, placebo-controlled, double-blind trial in early rehabilitation after stroke: better arm function on the Action Research Arm Test at day 90 with Cerebrolysin, though the authors call the study exploratory and ask for confirmation in a large trial.
- Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial - Stroke 2012: Large double-blind trial in 1070 patients with acute ischemic stroke: no significant difference from placebo in the confirmatory endpoint, with only a post hoc analysis of severe cases showing a trend in favor of Cerebrolysin.
- Cerebrolysin for acute ischaemic stroke - Cochrane Database of Systematic Reviews 2023: Cochrane review of seven randomized trials with 1773 participants: Cerebrolysin or similar peptide mixtures probably result in little to no difference in all-cause death after acute ischaemic stroke.
- Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials - Dementia and Geriatric Cognitive Disorders 2015: Meta-analysis of six randomized trials in mild-to-moderate Alzheimer’s disease: significantly better cognitive function than placebo at 4 weeks, a difference no longer significant at 6 months, while global clinical change remained better at both time points.
- Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke - Journal of Neuroscience Research 2010: In a rat model of embolic stroke, Cerebrolysin increased the number of neural progenitor cells in the subventricular zone and improved neurological tests without significantly reducing infarct volume.
